ইঙ্গিত ও ব্যবহার
Dacarzin এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
Malignant Melanoma: The recommended dose is 2 to 4.5 mg/kg per day for 10 days. The course may be repeated every 4 weeks. An alternative recommended dose is 250 mg/m2 per day by intravenous injection for 5 days, with the course repeated every 3 weeks. Hodgkin's Disease: The recommended dose of Dacarbazine for treating Hodgkin's disease is 150 mg/m2 per day for 5 days, given in combination with other effective drugs. The course may be repeated every 4 weeks. An alternative recommended dose is 375 mg/m2 on day 1, given in combination with other effective drugs, and repeated every 15 days.
পার্শ্বপ্রতিক্রিয়া
Loss of appetite, nausea and vomiting are the most common side effects of dacarbazine. More than 90% of patients experience them with the first few doses. Vomiting lasts 1 to 12 hours and is only partly and unpredictably relieved by phenobarbital and/or prochlorperazine. In rare cases, nausea and vomiting have been severe enough to require stopping Dacarzin for Injection. Diarrhoea has rarely been reported with Dacarzin for Injection. One helpful measure is to limit the patient's intake of food by mouth for 4 to 6 hours before treatment. Patients usually become tolerant of these symptoms quickly, which suggests a central nervous system mechanism may be involved, and the symptoms generally settle after the first 1 or 2 days.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Hospital admission is not always required, but facilities for adequate laboratory monitoring must be available. If Dacarzin leaks into the surrounding tissue (extravasation) during intravenous administration, it may cause tissue damage and severe pain. Local pain, burning and irritation at the injection site may be relieved by applying hot packs to the area. The carcinogenicity of Dacarzin has been studied in rats and mice. In rats, Dacarzin induced proliferative endocardial lesions, including fibrosarcomas and sarcomas. In mice, administration of Dacarzin led to the development of angiosarcomas of the spleen.
নিষেধাজ্ঞা
Dacarbazine should not be used in patients who have previously shown hypersensitivity to it.